# Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

> **NCT01542788** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 278 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** Placebo to match SOF
- **DRUG:** Placebo to match RBV

## Key facts

- **NCT ID:** NCT01542788
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-11
- **Final completion:** 2013-02
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542788, "Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01542788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*